Blar i Publikasjoner fra Cristin - St. Olavs hospital på forfatter "Waage, Anders"
-
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
Gregersen, Henrik; Peceliunas, Valdas; Remes, Kari; Schjesvold, Fredrik Hellem; Abildgaard, Niels; Nahi, Hareth; Andersen, Niels Frost; Vangsted, Annette Juul; Klausen, Tobias Wirenfeldt; Helleberg, Carsten; Carlson, Kristina; Frølund, Ulf Christian; Axelsson, Per; Stromberg, Olga; Blimark, Cecilie Hveding; Crafoord, Jacob; Tsykunova, Galina; Eshoj, Henrik Rode; Waage, Anders; Hansson, Markus; Gulbrandsen, Nina (Peer reviewed; Journal article, 2021)Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and ... -
Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival
Aass, Kristin Roseth; Nedal, Tonje Marie Vikene; Bouma, Siri Anshushaug; Tryggestad, Synne Stokke; Haukås, Einar; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese; Mjelle, Robin (Journal article; Peer reviewed, 2022) -
Content of endothelial progenitor cells in autologous stem cellgrafts predict survival after transplantation for multiplemyeloma
Blix, Egil Støre; Kildal, Anders Benjamin; Bertelsen, Eirin Listau; Waage, Anders; Myklebust, June; Kolstad, Arne; Husebekk, Anne (Peer reviewed; Journal article, 2015)Multiple myeloma (MM) is considered an incurable B cell malignancy, although many patients can benefit from high-dose therapy with autologous stem cell transplantation (ASCT) as a first-line treatment. In non-Hodgkin ... -
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study
Nielsen, Lene Kongsgaard; Stege, Claudia; Lissenberg-Witte, Birgit I.; van der Holt, Bronno; Mellqvist, Ulf-Henrik; Salomo, Morten; Bos, Gerard; Levin, Mark-David; Visser-Wisselaar, Heleen; Hansson, Markus; van der Velden, Annette W.G.; Deenik, Wendy; Coenen, Juleon; Hinge, Maja; Klein, Saskia K.; Tanis, Bea C.; Szatkowski, Damian Lukasz; Brouwer, Rolf E.; Westerman, Matthijs; Leys, Rineke; Sinnige, Harm A.M.; Haukås, Einar; van der Hem, Klaas G.; Durian, Marc F.; Gimsing, Peter; van de Donk, Niels; Sonneveld, Pieter; Waage, Anders; Abildgaard, Niels; Zweegman, Sonja (Peer reviewed; Journal article, 2019)Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ... -
Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients
Rampa, Christoph Samuel; Tian, Erming; Våtsveen, Thea Kristin; Buene, Glenn; Slørdahl, Tobias Schmidt; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2014)Background Hepatocyte growth factor (HGF) is a pleiotropic cytokine which can lead to cancer cell proliferation, migration and metastasis. In multiple myeloma (MM) patients it is an abundant component of the bone marrow. ... -
Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982–2017
Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2020)Population‐based studies from high‐quality nationwide cancer registries provide an important alternative to clinical trials in the assessment of the impact of modern myeloma treatment. Based on data from the Cancer Registry ... -
Patterns of previous and secondary malignancies in patients with multiple myeloma
Langseth, Øystein Olstad; Myklebust, Tor Åge; Johannessen, Tom Børge; Hjertner, Øyvind; Waage, Anders (Peer reviewed; Journal article, 2021)Objectives: In contrast to secondary primary malignancies (SPM) following multiple myeloma (MM), less is known about previous malignancies. We therefore conducted a population-based study to assess the patterns of previous ... -
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia
Zatula, Alexey; Dikic, Aida; Mulder, Teska Celine; Sharma, Animesh; Vågbø, Cathrine Broberg; Sousa, Mirta; Waage, Anders; Slupphaug, Geir (Peer reviewed; Journal article, 2017)Plasma cell leukemia is a rare and aggressive plasma cell neoplasm that may either originate de novo (primary PCL) or by leukemic transformation of multiple myeloma (MM) to secondary PCL (sPCL). The prognosis of sPCL is ... -
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
Palumbo, Antonio; Waage, Anders; Hulin, Cyrille; Beksac, M; Zweegman, Sonja; Gay, Francesca; Gimsing, Peter; Leleu, X; Wijermans, P; Sucak, G; Pezzatti, S; Juliusson, Gunnar; Pegourie, B; Schaafsma, Marije; Galli, M; Turesson, Ingemar; Kolb, B; van der Holt, B; Baldi, I; Rolke, Jürgen; Ciccone, G; Wetterwald, M; Lokhorst, H; Boccadoro, Mario; Rodon, P; Sonneveld, Pieter (Journal article; Peer reviewed, 2013)Treatment with melphalan-prednisone-thalidomide improves the outcome of patients with multiple myeloma and is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a ... -
Why do myeloma patients have bone disease? A historical perspective.
Børset, Magne; Sundan, Anders; Waage, Anders; Standal, Therese (Peer reviewed; Journal article, 2019)The question of how myeloma cells cause destruction of skeletal tissue has interested scientists for many years, and knowledge in this field has developed in parallel with the understanding of physiological bone remodeling. ...